Pharmacy DX 'enpas' Surpasses 10 Million Cumulative Patients Receiving Health Support Info! Strengthening Fee Calculation Support and Operational Efficiency Ahead of 2026 Dispensing Fee Revision
Digicle Inc.'s pharmacy DX solution 'enpas' reached 10 million patients. It automates pharmacist tasks, increasing information provided to hospitals by 5 times and supporting fee calculations for the 2026 revision.
📋 Article Processing Timeline
- 📰 Published: April 1, 2026 at 00:00
- 🔍 Collected: April 1, 2026 at 01:06 (1h 6m after Published)
- 🤖 AI Analyzed: April 22, 2026 at 03:51 (506h 45m after Collected)
Digicle Inc. (Headquarters: Minato-ku, Tokyo; Representative Director CEO: Kazuyuki Furuya; Representative Director COO: Yusuke Imai), a CARTA HOLDINGS group company engaged in retail DX and healthcare DX businesses, announces that its DX solution for dispensing pharmacies, 'enpas', has surpassed a cumulative total of 10 million patients (*2) who have received individually optimized health support information (*1).
(*1) Refers to explanations of side effects according to the patient's disease and medication status, advice on maintaining health, etc.
(*2) Actual figures as of March 2026.
As the evaluation of 'interpersonal tasks' becomes stricter with the 2026 (Reiwa 8) dispensing fee revision, 'enpas' significantly reduces the administrative work of pharmacists. In addition to cases where the amount of information provided to hospitals increased by approximately 5 times, the number of calculations for specific drug management guidance additions 1 and 3 has also expanded significantly. Through high-quality intervention, it maximizes the 'evaluation of interpersonal tasks', which is the cornerstone of pharmacy management, and simultaneously achieves stabilization of pharmacy management.
The Turning Point in Pharmacy Management and the 2026 (Reiwa 8) Dispensing Fee Revision
In the 2026 (Reiwa 8) dispensing fee revision, the shift from evaluating the 'act' of dispensing itself to evaluating based on the 'functions and track record' provided by the pharmacy has become more pronounced. Therefore, the need to promote the sophistication of interpersonal tasks and refine the value as a 'chosen family pharmacy' by patients is higher than ever.
In response to such changes in the business environment, 'enpas', together with partner pharmacies that have introduced the system, accumulates case studies and shares know-how to powerfully back up the 'systematization of high-quality intervention' that directly links the expertise of pharmacists to profitability.
Why does the introduction of 'enpas' maximize the track record of interpersonal tasks and the acquisition of additions?
The reason is that it 'standardizes' and 'streamlines' 'interpersonal tasks', which previously depended on the pharmacist's experience level and administrative time, using a system. By automating and visualizing the processes necessary for calculation, 'enpas' provides a mechanism to turn person-dependent tasks into solid revenue while reducing the burden on the frontline.
1. Systematizing information provision at 'appropriate timing'
In interpersonal tasks such as 'inhaler instruction addition', 'leftover drug management', and 'specific drug management instruction addition', which will be key points in the next revision, 'enpas' automatically prints and presents check sheets, side effect risks, countermeasures, RMPs (Risk Management Plans), instruction slips, etc. at the optimal timing based on the patient's prescription data.
Because it can standardize evidence-based guidance and track record reports to hospitals (inhaler instruction evaluation tables, tracing reports, etc.) without relying on the pharmacist's experience, stores that have introduced it have a track record of increasing the number of information provisions to medical institutions by about 5 times compared to before introduction. By the system supplementing increasingly complex calculation requirements, it supports the strengthening of a solid revenue base.
(*1) Refers to explanations of side effects according to the patient's disease and medication status, advice on maintaining health, etc.
(*2) Actual figures as of March 2026.
As the evaluation of 'interpersonal tasks' becomes stricter with the 2026 (Reiwa 8) dispensing fee revision, 'enpas' significantly reduces the administrative work of pharmacists. In addition to cases where the amount of information provided to hospitals increased by approximately 5 times, the number of calculations for specific drug management guidance additions 1 and 3 has also expanded significantly. Through high-quality intervention, it maximizes the 'evaluation of interpersonal tasks', which is the cornerstone of pharmacy management, and simultaneously achieves stabilization of pharmacy management.
The Turning Point in Pharmacy Management and the 2026 (Reiwa 8) Dispensing Fee Revision
In the 2026 (Reiwa 8) dispensing fee revision, the shift from evaluating the 'act' of dispensing itself to evaluating based on the 'functions and track record' provided by the pharmacy has become more pronounced. Therefore, the need to promote the sophistication of interpersonal tasks and refine the value as a 'chosen family pharmacy' by patients is higher than ever.
In response to such changes in the business environment, 'enpas', together with partner pharmacies that have introduced the system, accumulates case studies and shares know-how to powerfully back up the 'systematization of high-quality intervention' that directly links the expertise of pharmacists to profitability.
Why does the introduction of 'enpas' maximize the track record of interpersonal tasks and the acquisition of additions?
The reason is that it 'standardizes' and 'streamlines' 'interpersonal tasks', which previously depended on the pharmacist's experience level and administrative time, using a system. By automating and visualizing the processes necessary for calculation, 'enpas' provides a mechanism to turn person-dependent tasks into solid revenue while reducing the burden on the frontline.
1. Systematizing information provision at 'appropriate timing'
In interpersonal tasks such as 'inhaler instruction addition', 'leftover drug management', and 'specific drug management instruction addition', which will be key points in the next revision, 'enpas' automatically prints and presents check sheets, side effect risks, countermeasures, RMPs (Risk Management Plans), instruction slips, etc. at the optimal timing based on the patient's prescription data.
Because it can standardize evidence-based guidance and track record reports to hospitals (inhaler instruction evaluation tables, tracing reports, etc.) without relying on the pharmacist's experience, stores that have introduced it have a track record of increasing the number of information provisions to medical institutions by about 5 times compared to before introduction. By the system supplementing increasingly complex calculation requirements, it supports the strengthening of a solid revenue base.